Research programme: Ras inhibitors - Boehringer Ingelheim/Vanderbilt University
Latest Information Update: 16 Jan 2015
At a glance
- Originator Boehringer Ingelheim; Vanderbilt University
- Class Small molecules
- Mechanism of Action Ras protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer
Most Recent Events
- 14 Jan 2015 Early research in Cancer in USA (unspecified route)
- 14 Jan 2015 Early research in Cancer in Germany (unspecified route)